P/E at 37.25 vs Industry's 34.53: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Premium Above Industry Average

Sun Pharmaceutical Industries Ltd trades at a P/E of 37.25, which is approximately 7.9% higher than the Pharmaceuticals & Biotechnology sector average of 34.53. This premium suggests that investors are willing to pay more for the stock relative to its peers, potentially reflecting expectations of superior earnings growth or a perception of higher quality. However, the valuation premium also raises questions about whether the current price fully discounts risks or if it leaves limited room for upside — previously rated Strong Buy, what is Sun Pharmaceutical Industries Ltd’s current rating?

Performance Across Timeframes: Mixed Momentum

The stock’s performance over the past year has been robust, delivering a 9.90% return compared to the Sensex’s decline of 6.88%. This outperformance extends to the three-month period as well, with a 9.79% gain versus the Sensex’s 8.98% loss, indicating sustained strength in the medium term. The one-month return is particularly impressive at 13.42%, contrasting sharply with the sector’s negative returns and the Sensex’s 3.99% decline. Year-to-date, the stock has gained 10.09%, while the Sensex has fallen 11.55%, underscoring the stock’s resilience amid broader market weakness.

Shorter-term momentum is positive too, with a 0.70% gain over the past week and a 0.11% increase on the day of reporting, slightly outperforming the sector by 0.49%. The stock has also recorded a two-day consecutive gain streak, accumulating 1.56% returns in that period. This steady upward movement contrasts with the broader sector, where 13 out of 19 stocks have reported positive results, four remained flat, and two posted negative outcomes — does this sector context support continued strength for Sun Pharmaceutical Industries Ltd?

Moving Average Configuration: Bullish Across All Key Levels

The technical picture for Sun Pharmaceutical Industries Ltd is notably constructive. The stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, signalling a strong upward trend across both short and long-term horizons. This alignment suggests sustained buying interest and a positive momentum backdrop, which is not always the case for large-cap pharmaceuticals. The proximity to its 52-week high, just 0.38% away from Rs 1917.15, further emphasises the strength of the current rally — is this a genuine breakout or a temporary peak?

Sector Performance: Predominantly Positive Results

The Pharmaceuticals & Biotechnology sector has seen 19 stocks declare results recently, with 13 reporting positive outcomes, four flat, and two negative. This majority of positive results reflects a generally favourable environment for the sector, which may be supporting Sun Pharmaceutical Industries Ltd’s relative outperformance. The sector’s mixed but predominantly positive earnings backdrop contrasts with the broader market’s struggles, highlighting the defensive qualities often attributed to pharmaceutical stocks.

Rating Context: Previously Strong Buy, Now Reassessed

MarketsMOJO had previously assigned a Strong Buy rating to Sun Pharmaceutical Industries Ltd. The rating was updated on 18 May 2026, reflecting a reassessment of the stock’s fundamentals, valuation, and technicals. While the current rating is not disclosed, the change invites investors to consider how the stock’s premium valuation and recent performance align with their investment objectives — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Market Capitalisation and Large-Cap Status

With a market capitalisation of approximately ₹4,54,254.09 crore, Sun Pharmaceutical Industries Ltd firmly holds its position as a large-cap stock within the Pharmaceuticals & Biotechnology sector. This scale provides the company with significant resources and market influence, which can be a stabilising factor amid sector volatility. The stock’s ability to maintain gains across multiple timeframes and outperform the Sensex by wide margins over one, three, and twelve months reflects this strength.

Long-Term Performance: A Mixed Picture

Examining longer-term returns, the stock has delivered a 102.10% gain over three years, substantially outperforming the Sensex’s 21.65% rise. Over five years, the return is even more pronounced at 174.24%, compared to the Sensex’s 49.15%. However, the ten-year return of 139.03% trails the Sensex’s 197.93%, indicating that while the stock has been a strong performer in recent years, it has lagged the broader market over the last decade. This divergence may reflect sector-specific challenges or company-specific factors that have influenced performance over the longer term.

Summary: What the Data Collectively Shows

The data paints a picture of Sun Pharmaceutical Industries Ltd as a large-cap pharmaceutical stock trading at a modest premium to its sector, supported by strong medium-term performance and a bullish technical setup. The stock’s outperformance relative to the Sensex across multiple timeframes, combined with its position above all key moving averages, suggests sustained investor confidence. Yet, the premium valuation and the recent rating reassessment invite a closer look at whether the current price fully reflects the risks and opportunities inherent in the company’s outlook — what is the current rating for Sun Pharmaceutical Industries Ltd?

53% Discount is LIVE - Get MojoOne + Stock of the Week for 3 Years Start Today